The stock has demonstrated a strong and sustained uptrend over the past six months, with the price rising from the low $20s in October 2025 to above $40 by March 2026. The 3-month price change is a significant +78.14%, and the 1-month change is +35.54%, significantly outperforming the broader market (SPY) which declined over the same periods.

In the short term, the stock has shown exceptional momentum, with the 1-month gain of over 35% and a 3-month gain of over 78%. This performance is highlighted by a sharp rally from around $30 in early February 2026 to a recent high near $42.

The current price of $41.65 is near the top of its 52-week range of $20.40 to $42.74, trading at approximately 97.4% of its 52-week high. This indicates the stock is at a strong technical level, though it may be susceptible to a pullback from overbought conditions. Technical indicators like RSI are not provided.

Revenue and profitability have been volatile and under pressure. The most recent quarterly revenue (Q4 2025) was $9.46 billion, representing a year-over-year decline of -9.1%. The company reported a significant net loss of -$1.54 billion for the quarter, with a negative net margin of -16.3%, driven by substantial other expenses and a large operating loss. This contrasts with a profitable Q3 2025, indicating recent deterioration.

The company's financial health shows a debt-to-equity ratio of 1.22, indicating a leveraged balance sheet. Cash flow is a concern, with a trailing twelve-month free cash flow of -$2.61 billion. However, the latest quarterly operating cash flow was positive at $1.03 billion, and the current ratio of 1.97 suggests adequate short-term liquidity.

Operational efficiency metrics are weak, with a negative Return on Equity (ROE) of -16.4% and a negative Return on Assets (ROA) of -0.07%. The asset turnover and other efficiency ratios are not directly provided in the summary data, but the negative profitability metrics point to significant operational challenges in the recent quarter.